Characteristics | Normal (BMI < 25), n = 69 | Overweight (BMI ≥ 25 to < 30), n = 102 | Obese (BMI ≥ 30), n = 137 | p⋄ |
---|---|---|---|---|
Female, n (%) | 46 (67) | 77 (75) | 108 (79) | |
SJC66 | 19.0 (13.3) | 18.2 (10.6) | 18.2 (9.8) | 0.862 |
SJC28 | 13.0 (6.0) | 12.3 (5.8) | 11.8 (5.5) | 0.358 |
TJC68 | 30.0 (17.6) | 29.8 (16.1) | 33.0 (17.4) | 0.268 |
TJC28 | 16.2 (7.3) | 15.8 (7.2) | 16.5 (7.2) | 0.763 |
CRP, mg/l | 13.0 (22.5) | 16.3 (25.3) | 14.2 (17.3) | 0.583 |
Female | 10.1 (18.3) | 14.6 (22.9) | 14.9 (18.9) | |
Male | 18.9 (28.7) | 21.7 (31.2) | 11.5 (9.1) | |
DAS28-CRP* | 5.8 (1.0) | 5.8 (1.0) | 5.9 (0.9) | 0.762 |
CDAI† | 41.9 (13.5) | 40.2 (13.5) | 41.0 (12.2) | 0.692 |
HAQ-DI‡ | 1.4 (0.6) | 1.5 (0.6) | 1.5 (0.6) | 0.288 |
Synovial hypertrophy | 34.6 (7.4) | 34.0 (7.4) | 33.1 (7.2) | 0.346 |
Median (range) | 35.0 (8.0–46.0) | 35.0 (1.5–47.5) | 34.5 (6.0–45.0) | |
Synovial vascularity | 6.1 (5.5) | 6.5 (6.0) | 5.2 (4.8) | 0.143 |
Median (range) | 5.5 (0.0–26.5) | 5.0 (0.0–25.0) | 4.0 (0.0–25.5) | |
SF-36 PCS§ | 33.3 (8.4) | 31.7 (9.1) | 30.6 (8.0) | 0.113 |
SF-36 MCS§ | 44.1 (13.2) | 45.6 (11.9) | 41.3 (13.1) | 0.033 |
Observed data are reported. Data are mean (SD) unless indicated otherwise.
↵⋄ P value for differences between groups from 1-way ANOVA.
↵* Overweight group, n = 100; obese group, n = 133.
↵† Overweight group, n = 100; obese group, n = 132.
↵‡ Overweight group, n = 101; obese group, n = 135.
↵§ Normal group, n = 68; overweight group, n = 100; obese group, n = 134. BMI: body mass index; CDAI: Clinical Disease Activity Index; CRP: C-reactive protein; DAS28-CRP: 28-joint count Disease Activity Score using CRP; HAQ-DI: Health Assessment Questionnaire–Disability Index; MCS: mental component summary; PCS: physical component summary; SF-36: Medical Outcomes Study Short Form-36; SJC66: swollen joint count at 66 joints; SJC28: SJC at 28 joints; TJC68: tender joint count at 68 joints; TJC28: TJC at 28 joints.